Drug Trial Radar · NCT06989112
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Mar 27, 2025
Primary completion
Jan 19, 2029
Study completion Feb 19, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo Co., Ltd.; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Conditions
- Endometrial Cancer
Interventions
Trastuzumab deruxtecanDrug
Experimental therapy by intravenous infusion
RilvegostomigDrug
Experimental therapy by intravenous infusion
PembrolizumabDrug
Immunotherapy by intravenous infusion
CarboplatinDrug
Standard of Care (SoC) chemotherapy by intravenous infusion
PaclitaxelDrug
Standard of Care (SoC) chemotherapy by intravenous infusion
DocetaxelDrug
Standard of Care (SoC) chemotherapy by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS), as assessed by BICRTime frame: Until progression or death due to any cause (assessed up to approximately 45 months).
Locations
256 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona · Withdrawn
Research Site
Little Rock, Arkansas · Recruiting
Research Site
Duarte, California · Recruiting
Research Site
Irvine, California · Recruiting
Research Site
La Jolla, California · Recruiting
Research Site
Palo Alto, California · Withdrawn
Research Site
San Francisco, California · Not yet recruiting
Research Site
Sylmar, California · Withdrawn
Research Site
Fort Myers, Florida · Recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Miami Beach, Florida · Recruiting
Research Site
Orlando, Florida · Recruiting
Research Site
St. Petersburg, Florida · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
West Palm Beach, Florida · Recruiting
Research Site
Augusta, Georgia · Withdrawn
Research Site
Honolulu, Hawaii · Withdrawn
Research Site
Arlington Heights, Illinois · Recruiting
Research Site
Evanston, Illinois · Recruiting
Research Site
Shreveport, Louisiana · Recruiting
Research Site
Baltimore, Maryland · Recruiting
Research Site
Silver Spring, Maryland · Not yet recruiting
Research Site
Boston, Massachusetts · Recruiting
Research Site
Worcester, Massachusetts · Withdrawn
Research Site
Ann Arbor, Michigan · Recruiting
Research Site
Detroit, Michigan · Withdrawn
Research Site
Marshall, Minnesota · Recruiting
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Jackson, Mississippi · Recruiting
Research Site
Springfield, Missouri · Recruiting
Research Site
St Louis, Missouri · Recruiting
Research Site
Las Vegas, Nevada · Withdrawn
Research Site
Lebanon, New Hampshire · Recruiting
Research Site
Hackensack, New Jersey · Recruiting
Research Site
Albuquerque, New Mexico · Withdrawn
Research Site
New York, New York · Withdrawn
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Withdrawn
Research Site
Charlotte, North Carolina · Recruiting
Showing 40 of 256 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.